HEPA
NASDAQHepion Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.32+0.00 (+0.00%)
2026-02-052026-05-11
News · 26 weeks19-89%
2025-12-142026-06-07
Mix1690d
- SEC Filings8(50%)
- Insider8(50%)
Latest news
25 items- INSIDERNew insider Lopriore Chase claimed ownership of 1,250,000 shares (SEC Form 3)3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- SECSEC Form 10-Q filed by Hepion Pharmaceuticals Inc.10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form DEFA14A filed by Hepion Pharmaceuticals Inc.DEFA14A - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form DEF 14A filed by Hepion Pharmaceuticals Inc.DEF 14A - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- INSIDERDirector Purcell Michael J. bought $50,000 worth of shares (1,250,000 units at $0.04) (SEC Form 4)4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERExecutive Chairman Lopriore Vincent S bought $250,000 worth of shares (6,250,000 units at $0.04) (SEC Form 4)4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERInterim CEO Stetz Gary S. bought $50,000 worth of shares (1,250,000 units at $0.04) (SEC Form 4)4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERDirector Appajosyula Sireesh bought $50,000 worth of shares (1,250,000 units at $0.04) (SEC Form 4)4 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- SECSEC Form D filed by Hepion Pharmaceuticals Inc.D - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- INSIDERSEC Form 3 filed by new insider Stetz Gary S.3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 3 filed by Hepion Pharmaceuticals Inc.3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- INSIDERSEC Form 3 filed by Hepion Pharmaceuticals Inc.3 - Hepion Pharmaceuticals, Inc. (0001583771) (Issuer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form 10-K filed by Hepion Pharmaceuticals Inc.10-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECHepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- PRHepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular CarcinomaNext-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion's strategic shift to advancing clinically proven liquid biopsy tests under new leadership MORRISTOWN, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a precision diagnostics company, today announced that it has in-licensed from Cirna Diagnostics LLC, a novel biomarker assay that detects mutant circulating tumor RNA (ctRNA) to facilitate early diagnosis of hepatocellular carcinoma (HCC) in high-risk patients (cirrhosis). Most cases of liver cancer (75-90%) are HCC, and HCC is the sixth most common cancer w
- SECSEC Form 8-K filed by Hepion Pharmaceuticals Inc.8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form 10-Q filed by Hepion Pharmaceuticals Inc.10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Hepion Pharmaceuticals Inc.SCHEDULE 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
- SECSEC Form 10-Q filed by Hepion Pharmaceuticals Inc.10-Q - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- SECSEC Form 25-NSE filed by Hepion Pharmaceuticals Inc.25-NSE - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)
- SECSEC Form 8-K filed by Hepion Pharmaceuticals Inc.8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)
- PRHepion Pharmaceuticals Successfully Completes Application to the OTCQBMORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company's common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA. About Hepion Pharmaceuticals Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnost
HEPA FAQ
6 questionsWhat does Hepion Pharmaceuticals Inc. do?
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Where does HEPA stock trade?
Hepion Pharmaceuticals Inc. (HEPA) is listed on NASDAQ.What sector and industry is HEPA in?
Hepion Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about HEPA?
Hepion Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Cantor Fitzgerald: Overweight with a $350.00 price target on 2022-02-28. Recent price targets cluster around $350.00.What companies are similar to HEPA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare HEPA side-by-side with any of them on Quantisnow.How can I track HEPA on Quantisnow?
Quantisnow aggregates Hepion Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HEPA to receive live email and push alerts on every new disclosure.